The bolus thrombolytic agent tenecteplase narrowly failed to show noninferiority to alteplase in the TASTE clinical trial within 4.5 hours of symptom onset selected by perfusion imaging in patients ...

Making the switch from alteplase to tenecteplase for stroke thrombolysis can be done successfully when the appropriate preparations are taken, and it may improve patient outcomes, the experience of a ...

The approval marks the first new stroke treatment authorized in nearly 27 years, offering an additional option for managing acute ischemic stroke in Canada. MISSISSAUGA, ON, Dec. 17, 2025 /CNW/ - ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

The approval marks the first new stroke treatment authorized in nearly 27 years, offering an additional option for managing acute ischemic stroke in Canada. MISSISSAUGA, ON, Dec. 17, 2025 /CNW/ - ...

Patients with an ischemic stroke treated with tenecteplase have almost a 50% lower rate of symptomatic intracranial hemorrhage (sICH) compared with those receiving alteplase, preliminary results from ...

Patients with ischemic stroke due to large vessel occlusion (LVO) and proof of salvageable brain tissue were more likely to have no disability (modified Rankin scale scores 0-1) at 90 days if they had ...

PHOENIX -- Selected stroke patients did not benefit clinically from having the window of tenecteplase therapy extended beyond the first few hours of stroke onset, the randomized TIMELESS trial found.

An off-label clot-busting drug appears to work slightly better in treating stroke patients than an approved medication, a new review finds. Photo by Adobe Stock/HealthDay News An off-label ...

Please provide your email address to receive an email when new articles are posted on . In patients with moderate or severe ischemic stroke, a lower dose of IV tenecteplase yielded less favorable ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Treatment with IV Tenecteplase was not associated with ...

Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...